Alnylam Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. 

CEO
Yvonne L. Greenstreet
CEOYvonne L. Greenstreet
Employees
2,230
Employees2,230
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2002
Founded2002
Employees
2,230
Employees2,230

ALNY Key Statistics

Market cap
40.75B
Market cap40.75B
Price-Earnings ratio
1.34K
Price-Earnings ratio1.34K
Dividend yield
Dividend yield
Average volume
1.81M
Average volume1.81M
High today
$320.01
High today$320.01
Low today
$298.00
Low today$298.00
Open price
$314.42
Open price$314.42
Volume
2.88M
Volume2.88M
52 Week high
$495.55
52 Week high$495.55
52 Week low
$205.87
52 Week low$205.87

Stock Snapshot

With a market cap of 40.75B, Alnylam Pharmaceuticals(ALNY) trades at $308.48. The stock has a price-to-earnings ratio of 1340.60.

As of 2026-02-12, Alnylam Pharmaceuticals(ALNY) stock has fluctuated between $298.00 and $320.01. The current price stands at $308.48, placing the stock +3.5% above today's low and -3.6% off the high.

The Alnylam Pharmaceuticals(ALNY)'s current trading volume is 2.88M, compared to an average daily volume of 1.81M.

During the past year, Alnylam Pharmaceuticals(ALNY) stock moved between $205.87 at its lowest and $495.55 at its peak.

During the past year, Alnylam Pharmaceuticals(ALNY) stock moved between $205.87 at its lowest and $495.55 at its peak.

ALNY News

Simply Wall St 2h
Alnylam Pharmaceuticals Valuation Check After Swing To Profit On Strong 2025 Earnings

Advertisement What Alnylam’s latest earnings tell you Alnylam Pharmaceuticals (ALNY) just reported Q4 and full year 2025 results that moved from losses to pro...

Alnylam Pharmaceuticals Valuation Check After Swing To Profit On Strong 2025 Earnings
TipRanks 4h
Alnylam: ATTR Franchise Momentum and Strategic Investment Support Durable Growth and Buy Rating

Analyst Joseph Stringer of Needham maintained a Buy rating on Alnylam Pharma, reducing the price target to $510.00. Joseph Stringer has given his Buy rating du...

TipRanks 4h
Alnylam price target lowered to $444 from $508 at Stifel

Stifel analyst Paul Matteis lowered the firm’s price target on Alnylam (ALNY) to $444 from $508 and keeps a Buy rating on the shares. The firm notes that the qu...

Analyst ratings

70%

of 27 ratings
Buy
70.4%
Hold
29.6%
Sell
0%

More ALNY News

TipRanks 10h
Alnylam reports Q4 EPS $1.25, consensus $1.50

Reports Q4 revenue $1.1B, consensus $1.16B. “2025 was a year of key accomplishments for Alnylam (ALNY), highlighted by the landmark approval of AMVUTTRA for ATT...

People also own

Based on the portfolios of people who own ALNY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.